Study: Anti-microRNA sedate essentially lessens miR-92a levels in human peripheral blood

Overview

• Post By : Kumar Jeetendra


• Source: Mary Ann Liebert, Inc., Publishers


• Date: 12 Aug,2020

A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans.

“According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,” said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. “MRG-110 caused de-repression of gene goals in human peripheral blood cells”

This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,”-Graham C. Parker, PhD, Executive Editor, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI